AU2019254980B2 - Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy - Google Patents

Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy Download PDF

Info

Publication number
AU2019254980B2
AU2019254980B2 AU2019254980A AU2019254980A AU2019254980B2 AU 2019254980 B2 AU2019254980 B2 AU 2019254980B2 AU 2019254980 A AU2019254980 A AU 2019254980A AU 2019254980 A AU2019254980 A AU 2019254980A AU 2019254980 B2 AU2019254980 B2 AU 2019254980B2
Authority
AU
Australia
Prior art keywords
inhibitors
dna
tumor therapy
dual atm
atm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019254980A
Other versions
AU2019254980A1 (en
Inventor
Jianmin Fu
Tona Gilmer
Robert Goodnow
Michael Kastan
David Kirsch
Aijun Lu
Yue Sun
Yaode Wang
Guosheng Wu
Shuang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xrad Therapeutics Inc
Original Assignee
Xrad Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810359447.6A external-priority patent/CN110386932A/en
Application filed by Xrad Therapeutics Inc filed Critical Xrad Therapeutics Inc
Priority claimed from PCT/CN2019/083104 external-priority patent/WO2019201283A1/en
Publication of AU2019254980A1 publication Critical patent/AU2019254980A1/en
Application granted granted Critical
Publication of AU2019254980B2 publication Critical patent/AU2019254980B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2019254980A 2018-04-20 2019-04-17 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy Active AU2019254980B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810359447.6A CN110386932A (en) 2018-04-20 2018-04-20 For the dual ATM and DNA-PK inhibitor in antitumor therapy
CN201810359447.6 2018-04-20
US201862665296P 2018-05-01 2018-05-01
US62/665,296 2018-05-01
PCT/CN2019/083104 WO2019201283A1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Publications (2)

Publication Number Publication Date
AU2019254980A1 AU2019254980A1 (en) 2020-12-03
AU2019254980B2 true AU2019254980B2 (en) 2023-06-22

Family

ID=

Similar Documents

Publication Publication Date Title
EP3784671A4 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP3870579A4 (en) Tyk2 inhibitors and uses thereof
EP3742978A4 (en) Systems and methods for simultaneous multi-focus ultrasound therapy in multiple dimensions
EP3809967A4 (en) Systems and methods for physical therapy
HUE064592T2 (en) Peptide for use in immunotherapy against non-small cell lung cancer and small cell lung cancer
EP3934645A4 (en) Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment
EP3886843A4 (en) Tyk2 inhibitors and uses thereof
EP3866789A4 (en) Tyk2 inhibitors and uses thereof
EP3728270A4 (en) Macrocyclic kinase inhibitors and their use
EP3876956A4 (en) Systems and methods for targeting cancer cells
EP3706753A4 (en) Adenosine pathway inhibitors for cancer treatment
EP3430057A4 (en) Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
EP3700617A4 (en) Systems and methods for delivering neuroregenerative therapy
EP3600549A4 (en) Systems and methods for delivering radiotherapy
EP3946448A4 (en) Semi-synthetic biopolymers for use in stimulating the immune system
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
EP3806679A4 (en) Capsules for use in personal vaporizers
EP3754046A4 (en) Member for use in plasma treatment device, and plasma treatment device provided therewith
EP3570795A4 (en) Systems and methods for rapid contrast therapy
EP3463398A4 (en) Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
GB201702160D0 (en) Inhibitors for use in therapy
EP3820522A4 (en) Methods for detecting and treating cancers having adenosine pathway activation
EP3820520A4 (en) Methods for detecting and treating cancers having adenosine pathway activation
EP3763731A4 (en) Hmgn partial peptide and cancer therapy using same
IL289542A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy